Interestingly, the authors demonstrated that the combination of CAR-T treatment with a drug able to inhibit the AIM2 inflammasome (i.e., thalidomide) or to block of the α1-AR reversed the upregulation of PD-L1 and IDO and the phenotypic switch of the macrophages, limiting CAR-T therapy-associated toxic side effects and ensuring its anti-tumor effects (Table 1) [107]. The gene discussed is AIM2; the disease is neoplasm.